Funding for this research was provided by:
National Cancer Institute (R01 CA065823-24, F32CA239422, K08 CA245224-01)
American Society of Hematology (American Society of Hematology Scholar Award)
Gilead Foundation (Gilead Research Scholars Award)
American Cancer Society (RSG-19-184-01-LIB)
National Center for Advancing Translational Sciences (KL2 TR002370-03)
Howard Hughes Medical Institute
Received: 23 October 2020
Accepted: 18 January 2021
First Online: 30 January 2021
Ethics approval and consent to participate
: The OHSU IRB determined that the proposed activity is not research involving human subjects. Access and use of protected health information complies with OHSU HIPAA policies for non-research activities.
: Not applicable. Data presented in this study has been de-identified and contains none of the 18 HIPPA individual identifiers.
: B.J.D. potential competing interests–SAB: Aileron Therapeutics, ALLCRON, Cepheid, Vivid Biosciences, Celgene, RUNX1 Research Program, EnLiven Therapeutics, Gilead Sciences (inactive), Baxalta (inactive), Monojul (inactive); SAB and stock: Aptose Biosciences, Blueprint Medicines, Beta Cat, Third Coast Therapeutics, GRAIL (inactive), CTI BioPharma (inactive); scientific founder: MolecularMD (inactive, acquired by ICON); board of directors and stock: Amgen; board of directors: Burroughs Wellcome Fund, CureOne; joint steering committee: Beat AML LLS; founder: VP Therapeutics; clinical trial funding: Novartis, Bristol-Myers Squibb, Pfizer; royalties from Patent 6958335 (Novartis exclusive license) and OHSU and Dana- Farber Cancer Institute (one Merck exclusive license). B.J.D. potential competing interests– consultant: Monojul, Patient True Talk; SAB: Aileron Therapeutics, ALLCRON, Cepheid, Gilead Sciences, Vivid Biosciences, Celgene & Baxalta (inactive); SAB and stock: Aptose Biosciences, Blueprint Medicines, Beta Cat, GRAIL, Third Coast Therapeutics, CTI Bio-Pharma (inactive); scientific founder and stock: MolecularMD; board of directors and stock: Amgen; board of directors: Burroughs Wellcome Fund, CureOne; joint steering committee: Beat AML LLS; clinical trial funding: Novartis, Bristol-Myers Squibb, Pfizer; royalties: OHSU #606-Novartis exclusive license, OHSU #2573; Dana-Farber Cancer Institute #2063- Merck exclusive license. J.E.M. receives grant funding from the Gilead Research Scholars Program. The remaining authors declare no competing interests.